We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Targeted Microbubbles Enhance Ultrasound Detection of Malignant Tumors

By LabMedica International staff writers
Posted on 11 Apr 2017
By combining standard ultrasound technology with a novel type of targeted microbubbles, cancer researchers have developed a sensitive method for detecting malignant tumors that could reduce the number of biopsies needed to differentiate them from benign growths.

Investigators at Stanford University prepared one to four micron diameter phospholipid microbubbles containing a mixture of perfluorobutane and nitrogen gas that were labeled with kinase insert domain receptor (KDR) protein. More...
The result was a class of targeted contrast microbubbles (MBKDR) that was targeted at KDR, one of the key regulators of neoangiogenesis in cancer. KDR is found on tumor blood vessels but not in healthy tissue.

The investigators designed a study to assess whether ultrasound using MBKDR was safe and would allow assessment of KDR expression using immunohistochemistry (IHC) as the gold standard. They injected MBKDR intravenously into 24 women (age 48 to 79 years) with focal ovarian lesions and 21 women (age 34 to 66 years) with focal breast lesions. Ultrasound analysis of the lesions was performed starting five minutes after injection for up to 29 minutes. Blood pressure, ECG, oxygen levels, heart rate, CBC, and metabolic panel were obtained before and after MBKDR administration. Persistent focal MBKDR binding by ultrasound imaging was assessed. Patients then underwent surgical resection of the target lesions, and tissues were stained for CD31 and KDR by IHC.

Results revealed that ultrasound imaging with MBKDR was well tolerated by all patients without safety concerns. Among the 40 patients included in the analysis, KDR expression on IHC matched well with imaging signal on ultrasound imaging in 93% of breast and 85% of ovarian malignant lesions. Strong KDR-targeted ultrasound signals were present in 77% of malignant ovarian lesions, with no targeted signal seen in 78% of benign ovarian lesions. Similarly, strong targeted signals were seen in 93% of malignant breast lesions with no targeted signal present in 67% of benign breast lesions.

"The difficulty with ultrasound right now," said first author Dr. Jürgen Willmann, professor of radiology at Stanford University, "is that it detects a lot of lesions in the breast, but most of them are benign. And that leads to many unnecessary biopsies and surgeries. To decrease those unnecessary biopsies and surgeries would be a huge leap forward. We could make ultrasound a highly accurate screening technology that is relatively low cost, highly available, and with no radiation. And since ultrasound technology is accessible almost everywhere, he said, the technology could potentially help patients all over the world."

The targeted microbubble technique was described in the March 14, 2017, online edition of the Journal of Clinical Oncology.


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Prefilled Tubes
Prefilled 5.0ml Tubes
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A new study identifies distinct metabolomic signatures in maternal blood associated with both the timing and type of early birth (Image credit: iStock)

Maternal Blood Biomarkers Identify Risk of Preterm and Early-Term Birth

Preterm and early-term births can lead to lasting complications because vital organs continue to mature during the final weeks of pregnancy. Babies born too soon face increased risks of breathing difficulties,... Read more

Molecular Diagnostics

view channel
Image: The Fast PCR System delivers sample‑to‑answer results for key pathogens in under 10 minutes (Photo courtesy of Autonomous Medical Devices Incorporated)

Point-of-Care PCR Panel Detects RSV, Influenza, and SARS-CoV-2 in Minutes

Respiratory syncytial virus, influenza, and SARS-CoV-2 remain major respiratory pathogens in ambulatory care. RSV is a particular priority because it can cause significant disease in infants, older adults,... Read more

Microbiology

view channel
Image: Burkholderia pseudomallei is a soil-dwelling bacterium that causes melioidosis, a severe and potentially fatal infection that remains difficult to diagnose (Image Credit: Gavin Koh/Wikimedia Commons, CC BY-SA 4.0)

Stronger Laboratory Services Support Timely Melioidosis Diagnosis Amid Global Spread

Melioidosis, a potentially fatal infection caused by Burkholderia pseudomallei, remains difficult to recognize because its symptoms can mimic tuberculosis and other illnesses. The disease is considered... Read more

Industry

view channel
Image

QIAGEN Enhances QIAcuity Platform with Gene Expression and Multiplexing Tools

QIAGEN (Venlo, Netherlands) has introduced additions to its QIAcuity dPCR ecosystem that focus on gene expression, expanded assay content, and workflow standardization for life sciences and biopharma users.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.